AU2001284373A1 - Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents - Google Patents
Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agentsInfo
- Publication number
- AU2001284373A1 AU2001284373A1 AU2001284373A AU8437301A AU2001284373A1 AU 2001284373 A1 AU2001284373 A1 AU 2001284373A1 AU 2001284373 A AU2001284373 A AU 2001284373A AU 8437301 A AU8437301 A AU 8437301A AU 2001284373 A1 AU2001284373 A1 AU 2001284373A1
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- cell
- cells
- label
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 161
- 108090000623 proteins and genes Proteins 0.000 title claims description 89
- 102000004169 proteins and genes Human genes 0.000 title claims description 65
- 238000012216 screening Methods 0.000 title description 51
- 239000013543 active substance Substances 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 284
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 197
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 195
- 229920001184 polypeptide Polymers 0.000 claims description 194
- 210000003463 organelle Anatomy 0.000 claims description 75
- 230000001413 cellular effect Effects 0.000 claims description 61
- 108091033319 polynucleotide Proteins 0.000 claims description 59
- 102000040430 polynucleotide Human genes 0.000 claims description 59
- 239000002157 polynucleotide Substances 0.000 claims description 59
- 239000000470 constituent Substances 0.000 claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 208000019581 Abnormal cellular phenotype Diseases 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 22
- 238000009826 distribution Methods 0.000 claims description 20
- 238000002372 labelling Methods 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 14
- 230000004807 localization Effects 0.000 claims description 14
- 230000008045 co-localization Effects 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 230000008520 organization Effects 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 108091006047 fluorescent proteins Proteins 0.000 claims description 9
- 102000034287 fluorescent proteins Human genes 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 230000002285 radioactive effect Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- 238000000386 microscopy Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 229930014626 natural product Natural products 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 description 52
- 230000006870 function Effects 0.000 description 17
- 238000013519 translation Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 12
- 230000036457 multidrug resistance Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000010219 correlation analysis Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- DDVBPZROPPMBLW-ZJBINBEQSA-N latrunculin a Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](/C=C\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-ZJBINBEQSA-N 0.000 description 7
- DDVBPZROPPMBLW-UHFFFAOYSA-N latrunculin-A Natural products O1C(=O)C=C(C)CCC=CC=CC(C)CCC(O2)CC1CC2(O)C1CSC(=O)N1 DDVBPZROPPMBLW-UHFFFAOYSA-N 0.000 description 7
- 230000004853 protein function Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 229910052693 Europium Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- 230000004960 subcellular localization Effects 0.000 description 5
- 108010043137 Actomyosin Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 101000776197 Human papillomavirus type 16 Probable protein E5 Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 210000003850 cellular structure Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001650 focal adhesion Anatomy 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 102000018546 Paxillin Human genes 0.000 description 3
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 3
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229910052747 lanthanoid Inorganic materials 0.000 description 3
- 150000002602 lanthanoids Chemical class 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 102000016362 Catenins Human genes 0.000 description 2
- 108010067316 Catenins Proteins 0.000 description 2
- 102000003727 Caveolin 1 Human genes 0.000 description 2
- 108090000026 Caveolin 1 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000008068 Tensins Human genes 0.000 description 2
- 108010088950 Tensins Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 101710159648 Uncharacterized protein Proteins 0.000 description 2
- 210000002867 adherens junction Anatomy 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004323 caveolae Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 229940124606 potential therapeutic agent Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000026447 protein localization Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 108020001568 subdomains Proteins 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- JQDZUSDVVHXANW-UHFFFAOYSA-N C1=CC(=C23)C4=NC5=CC=CC=C5N4C(=O)C2=CC=CC3=C1NCCN1CCOCC1 Chemical compound C1=CC(=C23)C4=NC5=CC=CC=C5N4C(=O)C2=CC=CC3=C1NCCN1CCOCC1 JQDZUSDVVHXANW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000009193 Caveolin Human genes 0.000 description 1
- 108050000084 Caveolin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 241001137872 Leishmania sp. Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000030229 desmoplastic infantile ganglioglioma Diseases 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 102000026415 nucleotide binding proteins Human genes 0.000 description 1
- 108091014756 nucleotide binding proteins Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002005 protein protein interaction detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000002762 protein-protein interaction assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 108091012783 tubulin binding proteins Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22842000P | 2000-08-29 | 2000-08-29 | |
| US60/228,420 | 2000-08-29 | ||
| US30645701P | 2001-07-20 | 2001-07-20 | |
| US60/306,457 | 2001-07-20 | ||
| PCT/IL2001/000813 WO2002018537A2 (fr) | 2000-08-29 | 2001-08-29 | Methodes d'isolation de genes codant des proteines a fonction specifique et de criblage d'agents actifs d'un point de vue pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001284373A1 true AU2001284373A1 (en) | 2002-03-13 |
Family
ID=26922359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001284373A Abandoned AU2001284373A1 (en) | 2000-08-29 | 2001-08-29 | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060240404A1 (fr) |
| EP (1) | EP1313883A4 (fr) |
| JP (1) | JP2004520014A (fr) |
| AU (1) | AU2001284373A1 (fr) |
| CA (1) | CA2417233A1 (fr) |
| IL (1) | IL154128A0 (fr) |
| WO (1) | WO2002018537A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8131053B2 (en) | 1999-01-25 | 2012-03-06 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
| US7450229B2 (en) | 1999-01-25 | 2008-11-11 | Amnis Corporation | Methods for analyzing inter-cellular phenomena |
| US8885913B2 (en) | 1999-01-25 | 2014-11-11 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
| US8406498B2 (en) | 1999-01-25 | 2013-03-26 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
| US7907765B2 (en) | 2001-03-28 | 2011-03-15 | University Of Washington | Focal plane tracking for optical microtomography |
| US6636623B2 (en) * | 2001-08-10 | 2003-10-21 | Visiongate, Inc. | Optical projection imaging system and method for automatically detecting cells with molecular marker compartmentalization associated with malignancy and disease |
| US7738945B2 (en) | 2002-04-19 | 2010-06-15 | University Of Washington | Method and apparatus for pseudo-projection formation for optical tomography |
| US7260253B2 (en) | 2002-04-19 | 2007-08-21 | Visiongate, Inc. | Method for correction of relative object-detector motion between successive views |
| US8150136B2 (en) | 2004-03-16 | 2012-04-03 | Amnis Corporation | Image based quantitation of molecular translocation |
| US8953866B2 (en) | 2004-03-16 | 2015-02-10 | Amnis Corporation | Method for imaging and differential analysis of cells |
| US7630849B2 (en) * | 2005-09-01 | 2009-12-08 | Applied Biosystems, Llc | Method of automated calibration and diagnosis of laboratory instruments |
| US8114615B2 (en) | 2006-05-17 | 2012-02-14 | Cernostics, Inc. | Method for automated tissue analysis |
| US20100112602A1 (en) * | 2006-11-10 | 2010-05-06 | Taylor Lansing D | Protein-Protein Interaction Biosensors and Methods of Use Thereof |
| US7835561B2 (en) | 2007-05-18 | 2010-11-16 | Visiongate, Inc. | Method for image processing and reconstruction of images for optical tomography |
| US7787112B2 (en) | 2007-10-22 | 2010-08-31 | Visiongate, Inc. | Depth of field extension for optical tomography |
| WO2011138778A2 (fr) | 2010-05-04 | 2011-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Procédés permettant d'identifier des inhibiteurs de polypeptides d'intérêt |
| AU2012229102B2 (en) | 2011-03-17 | 2016-02-04 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
| US11069054B2 (en) | 2015-12-30 | 2021-07-20 | Visiongate, Inc. | System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639949A (en) * | 1990-08-20 | 1997-06-17 | Ciba-Geigy Corporation | Genes for the synthesis of antipathogenic substances |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| WO1999055886A1 (fr) * | 1998-04-24 | 1999-11-04 | Genova Pharmaceuticals Corporation | Decouverte de genes fonctionnels |
| JP2003509060A (ja) * | 1999-09-17 | 2003-03-11 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | 逆トランスフェクション方法 |
-
2001
- 2001-08-29 CA CA002417233A patent/CA2417233A1/fr not_active Abandoned
- 2001-08-29 AU AU2001284373A patent/AU2001284373A1/en not_active Abandoned
- 2001-08-29 WO PCT/IL2001/000813 patent/WO2002018537A2/fr not_active Application Discontinuation
- 2001-08-29 IL IL15412801A patent/IL154128A0/xx unknown
- 2001-08-29 JP JP2002524040A patent/JP2004520014A/ja active Pending
- 2001-08-29 EP EP01963353A patent/EP1313883A4/fr not_active Withdrawn
-
2006
- 2006-04-03 US US11/395,172 patent/US20060240404A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL154128A0 (en) | 2003-07-31 |
| EP1313883A2 (fr) | 2003-05-28 |
| US20060240404A1 (en) | 2006-10-26 |
| WO2002018537A3 (fr) | 2002-07-25 |
| CA2417233A1 (fr) | 2002-03-07 |
| JP2004520014A (ja) | 2004-07-08 |
| EP1313883A4 (fr) | 2005-01-12 |
| WO2002018537A2 (fr) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060240404A1 (en) | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents | |
| Ryan et al. | The nuclear pore complex: a protein machine bridging the nucleus and cytoplasm | |
| Lin et al. | eIF3 associates with 80S ribosomes to promote translation elongation, mitochondrial homeostasis, and muscle health | |
| Bernad et al. | Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export | |
| Teh et al. | The AP-1 µ adaptin is required for KNOLLE localization at the cell plate to mediate cytokinesis in Arabidopsis | |
| Starkuviene et al. | The potential of high‐content high‐throughput microscopy in drug discovery | |
| Ayaydin et al. | Distinct in vivo dynamics of vertebrate SUMO paralogues | |
| Wachtler et al. | Sterol-rich plasma membrane domains in the fission yeast Schizosaccharomyces pombe | |
| Schwartz et al. | BIM1 encodes a microtubule-binding protein in yeast | |
| Scherl et al. | Functional proteomic analysis of human nucleolus | |
| Montpetit et al. | Sumoylation of the budding yeast kinetochore protein Ndc10 is required for Ndc10 spindle localization and regulation of anaphase spindle elongation | |
| Palancade et al. | Pml39, a novel protein of the nuclear periphery required for nuclear retention of improper messenger ribonucleoparticles | |
| Pearson et al. | Yeast kinetochores do not stabilize Stu2p-dependent spindle microtubule dynamics | |
| Zwerger et al. | Induction of a massive endoplasmic reticulum and perinuclear space expansion by expression of lamin B receptor mutants and the related sterol reductases TM7SF2 and DHCR7 | |
| Kroetz et al. | Essential role of nuclear localization for yeast Ulp2 SUMO protease function | |
| Nascimento et al. | High‐throughput detection and quantification of mitochondrial fusion through imaging flow cytometry | |
| Kramer-Hämmerle et al. | Identification of a novel Rev-interacting cellular protein | |
| Bachellier-Bassi et al. | Cell cycle-dependent kinetochore localization of condensin complex in Saccharomyces cerevisiae | |
| EP1683874A2 (fr) | Méthode pour l'isolement de gènes codant pour des protéines à fonction spécifique et pour le criblage d'agents pharmaceutiques actifs | |
| US20040115659A1 (en) | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents | |
| EP3172563B1 (fr) | Procédés pour détecter des interactions dans des cellules eucaryotes au moyen de structures de microtubules et dynamiques | |
| Ma et al. | Cryo-ET detects bundled triple helices but not ladders in meiotic budding yeast | |
| Connolly et al. | The Arf-GTPase-activating protein Gcs1p is essential for sporulation and regulates the phospholipase D Spo14p | |
| WO2010003908A1 (fr) | Dosage utilisable pour le criblage de composés ciblant le complexe aaa-atpase p97 dans le système ubiquitine/protéasome | |
| Spector et al. | Transfection of mammalian cells with fluorescent protein fusions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |